The Market LogEnter at least 2 characters. Company and ticker searches are not case-sensitive.

Transaction #18880 · Form 4 · 0001140361-25-045409

Immunovant, Inc. · Purchase · Common Stock, $0.0001 par value per share

Immunovant, Inc. · Transacted December 12, 2025 · Filed December 12, 2025

Original SEC filing ↗

What does this filing report?

An SEC Form 4 filing for Immunovant, Inc. records a purchase involving Common Stock, $0.0001 par value per share on December 12, 2025. The reported quantity was 16,666,666. The filing date is December 12, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.

The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.

Transaction details

Company CIK
0001764013
Security type
Non-derivative
Acquisition type
Purchase · Code P
Quantity acquired
16,666,666
Reported price
21
Reference value
349,999,986
Currency
Currency not specified
Ownership
Direct
Holdings after transaction
113,317,007
Ownership description
Not reported
SEC acceptance time
Dec 12, 2025, 5:17 PM EST
10b5-1 indication
Not indicated

Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.

Reporting owners

These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.

Company listings

IMVT · Nasdaq

This transaction is not mapped to a specific company listing.

Filing footnotes & remarks

No footnotes are available in this record.

Remarks

The Reporting Person is deemed to be a "director by deputization" of the Issuer for purposes of Section 16 of the Securities Exchange Act of 1934 by virtue of the fact that Frank M. Torti, M.D. (who serves as President & Vant Chair of Roivant Sciences, Inc. ("RSI"), a subsidiary of the Reporting Person), Eric Venker, M.D., Pharm.D. (who serves as President of RSI) and Andrew Fromkin (who serves as the Vant Portfolio Operating Partner for RSI) each currently serve on the board of directors of the Issuer on behalf of the Reporting Person.

Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.

This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.